Caribou Biosciences Inc.

In News

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Yahoo Finance

Yahoo Finance - Mar 31, 2026

FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan

Stock Titan - Mar 31, 2026

Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha

Seeking Alpha - Mar 31, 2026

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - marketscreener.com

marketscreener.com - Mar 31, 2026

Caribou Biosciences Gains RMAT Status for CB-011 Therapy - tipranks.com

tipranks.com - Mar 31, 2026

Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - tradingview.com

tradingview.com - Mar 31, 2026

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference - marketbeat.com

marketbeat.com - Mar 14, 2026

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - Investing News Network

Investing News Network - Nov 02, 2025

FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan

Stock Titan - Mar 31, 2026

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance

Yahoo Finance - Mar 05, 2026

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha

Seeking Alpha - Mar 17, 2026

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Yahoo Finance - Mar 05, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment